Dextropropoxyphene/paracetamol - Xanodyne

Drug Profile

Dextropropoxyphene/paracetamol - Xanodyne

Alternative Names: Propoxyphene/acetaminophen - Xanodyne; XP 20B

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AAIPharma
  • Developer Xanodyne Pharmaceuticals
  • Class Acetanilides; Antipyretics; Non-opioid analgesics; Opioid analgesics; Propionates; Small molecules
  • Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute pain

Most Recent Events

  • 31 Dec 2010 No development reported - Phase-III for Acute pain in USA (PO)
  • 28 May 2008 Phase-III clinical trials for Acute pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top